Galectin‐3 could be an immunosuppressive molecule involved in tumor scape from immune surveillance with the TME implicated so we proposed to study the expression and secretion of GAL‐3 on 3D models of lung tumor cells analyzing its influence on TREGS. Moreover, as the clinical importance on recurrence of GAL‐3 after surgery in NSCLC patients has not been elucidated fully, we aimed to evaluate the prognostic and recurrence predictive value of soluble GAL‐3 (sGAL‐3) on these patients. The gene discussed is LGALS3; the disease is non-small cell lung carcinoma.